Please login to the form below

Not currently logged in
Email:
Password:

safinamide

This page shows the latest safinamide news and features for those working in and with pharma, biotech and healthcare.

FDA approves Newron's Parkinson's disease drug Xadago

FDA approves Newron's Parkinson's disease drug Xadago

Newron Pharmaceuticals’Xadago (safinamide) was approved as an add-on treatment for patients already on levodopa/carbidopa and who experience ‘off’episodes when those medications don’t work well.

Latest news

  • Newron back on track for Xadago approval in US Newron back on track for Xadago approval in US

    The Italian pharma company's partner Zambon is already rolling Xadago (safinamide) out in Europe following its EMA approval last year, and has just launched in Norway taking the tally of ... We assume the safinamide label could be expanded to include

  • Rare disease therapies head the ‘class of 2015’ Rare disease therapies head the ‘class of 2015’

    neprilysin inhibitor. Novartis. USA. safinamide. Xadago. Parkinson's disease. MAO-B inhibitor. Newron Pharma.

  • Chasing the cure for Parkinson's disease Chasing the cure for Parkinson's disease

    Currently available therapies of this class include selegiline and rasagiline. Safinamide (Newron, Zambon and Meiji Seika Pharma) is a selective and reversible MAO B inhibitor in the absence of MAO-A

  • Pharma deals for June 2012 Pharma deals for June 2012

    Elan. Newron Pharmaceuticals shows further signs of moving on from Merck Serono's decision in 2011 to return the rights to safinamide, which in turn prompted Biotie to abandon its planned

  • Pharma deals for May 2012 Pharma deals for May 2012

    Licence. Safinamide for Parkinson's Disease (P3). 25. Hemosphere / CryoLife. Acquisition.

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics